Kratom is not approved for any medical use in the United States, but millions of people use it on their own to manage chronic pain, ease opioid withdrawal, and treat symptoms of anxiety and depression. The plant, native to Southeast Asia, contains alkaloids that interact with opioid receptors in the brain, producing effects that range from mild stimulation at low doses (1 to 5 grams) to pain relief and sedation at higher doses (5 to 15 grams). Its medical potential is real but unproven in the formal sense: no clinical trials have established safe, effective dosing for any condition, and the FDA has not approved any kratom-containing drug products.
How Kratom Works in the Body
Kratom leaves contain more than 40 alkaloids, but two do most of the heavy lifting. Mitragynine makes up 40% to 60% of the total alkaloid content and is primarily responsible for the effects most users experience. The second, 7-hydroxymitragynine, is present in much smaller amounts but binds to opioid receptors roughly nine times more tightly than mitragynine does.
Both compounds preferentially target the same type of opioid receptor that medications like morphine and oxycodone activate. 7-hydroxymitragynine binds to this receptor with about three times greater affinity than it does to the body’s other opioid receptor types. This selectivity explains why kratom can reduce pain and produce mild euphoria, though its overall effect profile is more complex than a standard opioid. Mitragynine also interacts with adrenergic, serotonin, dopamine, and adenosine receptors, which accounts for kratom’s unusually broad range of effects.
Once consumed as a tea or powder, kratom alkaloids reach detectable levels in the blood within 15 minutes. Mitragynine hits peak concentration in about an hour, but it lingers in the body far longer than most people expect. Its half-life is roughly 45 hours, meaning it takes nearly two days for your body to clear just half of a single dose. This long half-life likely contributes to the sustained effects some users report and may also increase the risk of accumulation with frequent use.
Chronic Pain Relief
Pain management is the most common reason people use kratom. In a large survey conducted by researchers at Johns Hopkins, 91% of kratom users reported taking it to alleviate pain, most commonly in the back, shoulders, and knees. Users typically consumed it a couple of times per day.
At higher doses (5 to 15 grams), kratom’s opioid receptor activity produces analgesic effects similar in character to traditional painkillers, though generally milder. The mechanism is straightforward: mitragynine and 7-hydroxymitragynine activate the same pain-dampening pathways that prescription opioids do. What makes kratom different, at least in theory, is that its alkaloids appear to act as partial agonists at opioid receptors rather than full agonists. This distinction matters because partial activation tends to produce less respiratory depression, which is the primary way opioid overdoses kill people. However, this safety margin has not been rigorously established in controlled human studies.
Opioid Withdrawal Management
The second most discussed medical application is using kratom to manage opioid withdrawal. Because mitragynine activates opioid receptors, it can partially substitute for drugs like heroin, oxycodone, or fentanyl during withdrawal, easing symptoms like muscle aches, nausea, and agitation. Clinical case reports have documented patients successfully using kratom tea multiple times daily to avert withdrawal when their usual opioid was unavailable.
Mitragynine also appears to stimulate alpha-2 adrenergic receptors, mimicking the mechanism of clonidine, a medication commonly prescribed as a withdrawal aid. This dual action, hitting both opioid and adrenergic pathways, may explain why some people find kratom more effective than either approach alone.
The tradeoff is that kratom itself produces dependence. Stopping regular kratom use after a period of daily consumption can cause its own withdrawal symptoms, including runny nose, insomnia, difficulty concentrating, low mood, and muscle pain. In documented cases, these symptoms persisted for about 10 days. That said, researchers have noted that kratom withdrawal appears substantially milder than withdrawal from traditional opioids, a finding that has fueled interest in kratom as a potential bridge therapy.
Anxiety and Depression
In the same Johns Hopkins survey, 67% of users reported taking kratom for anxiety and 65% for depression. These numbers are self-reported and don’t come from controlled trials, but the pharmacology offers a plausible explanation for why people experience mood benefits.
Mitragynine interacts with serotonin receptors, including the 5-HT2C subtype that is also targeted by common antidepressants like fluoxetine (Prozac). It also binds to D2 dopamine receptors, which are the primary target of antipsychotic medications. Research published in The Yale Journal of Biology and Medicine suggests this combination of serotonin and dopamine activity could make kratom’s alkaloids relevant to treating depression, anxiety, and potentially even psychotic symptoms. Animal studies have found that kratom leaf extract at sufficient doses reduced psychotic-like behaviors, with the proposed mechanism being dopamine receptor activity for positive symptoms (like hallucinations) and serotonin receptor antagonism for negative symptoms (like emotional flatness and low motivation).
None of this has been tested in human clinical trials for psychiatric conditions. The gap between “interacts with the right receptors” and “works safely as a treatment” is enormous, and kratom’s complex pharmacology means its psychiatric effects could easily vary in unpredictable ways between individuals.
The Stimulant Effect at Low Doses
In Southeast Asia, kratom has been used for centuries by manual laborers seeking increased energy and endurance. At low doses of 1 to 5 grams, the stimulant effects predominate: increased alertness, sociability, and physical energy. This is the dose range where kratom’s interaction with adrenergic and adenosine receptors likely plays a larger role relative to its opioid activity. Many users in the U.S. take low-dose kratom as a substitute for caffeine or as a productivity aid, though no formal research has evaluated its effectiveness or safety for this purpose.
Drug Interaction Risks
One of kratom’s most clinically significant risks involves how it affects your liver’s ability to process other medications. Mitragynine is a potent inhibitor of CYP2D6, a liver enzyme responsible for breaking down roughly 25% of all prescription drugs. When this enzyme is blocked, medications that depend on it can build up to dangerously high levels in the bloodstream.
Drugs metabolized by CYP2D6 include many common antidepressants, beta-blockers, certain pain medications, and some antipsychotics. Kratom alkaloids also moderately inhibit CYP2C19 and one form of CYP3A4, broadening the list of potential interactions further. If you take prescription medications of any kind, the interaction risk with regular kratom use is not trivial.
Liver Injury and Other Safety Concerns
Kratom-associated liver injury is uncommon but well-documented. A review from the U.S. Drug Induced Liver Injury Network identified 11 confirmed cases, with a typical onset of symptoms within 5 to 28 days of starting use (median of 14 days). The pattern skews toward younger adults, with a median age of 32 and a male majority. Common symptoms include abdominal discomfort and jaundice, and liver biopsies typically show a pattern of bile flow disruption rather than direct cell destruction.
Published reviews have catalogued at least 26 cases total. The absolute numbers are small relative to the estimated millions of kratom users, but the short, predictable timeline from first use to symptom onset suggests a direct toxic or immune-mediated mechanism rather than coincidence. Yellowing of the skin or eyes, dark urine, or persistent abdominal pain within the first month of use warrants immediate medical attention.
Regulatory Status
The FDA has taken a cautious but increasingly engaged stance. No prescription or over-the-counter drug products containing kratom or its alkaloids are legally marketed in the United States. The agency has stated it would review a new drug application for kratom if one were submitted, but none has been approved to date.
In September 2024, the FDA awarded a grant for a human abuse potential study on kratom, building on an earlier single-dose safety study the agency funded. These are early steps in the kind of formal evaluation that could eventually lead to regulated medical products. Drug companies interested in developing kratom-based therapies have been encouraged to engage with the FDA’s drug review division, signaling that the agency considers the science worth pursuing even as it maintains that current unregulated products are not proven safe or effective.